Childhood cancer
Conditions
Interventions
Trade Name: Ciprofloxacine 100mg/5mL oplossing voor infusie
Product Name: ciprofloxacine
Pharmaceutical Form: Solution for infusion
Sponsors
UZ Brussel
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Children who • are between 1 month and 18 years of age • are under treatment for any type of childhood cancer • use ciprofloxacin intravenous for selective bowel decontamination as part of regular treatment • have a PAC (port a cath) for intravenous medication and blood draws. Are the trial subjects under 18? yes Number of subjects for this age range: 15 F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Children will be excluded from this study if we are unable to • obtain informed consent of both parents and assent of the child (if he/she is over 12 years of age) • aspire blood from the PAC (port a cath).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Investigating the agreement of ciprofloxacin concentrations between blood drawn via a central venous device (Port A Cath) versus via capillary sampling in pediatric cancer patients.;Secondary Objective: Not applicable.;Primary end point(s): Correlation per participant for ciprofloxacin concentrations drawn via PAC (port a cath) and via capillary sampling.;Timepoint(s) of evaluation of this end point: Concomittant blood draws. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): none;Timepoint(s) of evaluation of this end point: None | — |
Countries
Belgium
Contacts
Public ContactBimetra Clinics
Ghent University Hospital
Outcome results
None listed